NCT06751017View on ClinicalTrials.gov

A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 17, 2024

Primary Completion Date

February 24, 2025

Study Completion Date

February 24, 2025

Conditions
COVID-19
Interventions
DRUG

S-892216

S-892216 will be administered orally as a tablet.

DRUG

Carbamazepine

Carbamazepine will be administered orally as a tablet.

Trial Locations (1)

66219

ICON Lenexa, Lenexa

Sponsors

Lead Sponsor

Shionogi
All Listed Sponsors
lead

Shionogi

INDUSTRY